Answers are grounded in this paper and cite their sources.
Review synthesizes mechanisms of Akkermansia muciniphila in inflammation-related diseases, suggesting therapeutic potential.
Chronic inflammatory diseases, closely linked to gut microbiota dysbiosis, pose a major global health burden. Akkermansia muciniphila ( A. muciniphila ), a key gut commensal, sustains immune homeostasis and metabolic balance, emerging as a promising next-generation probiotic. This review synthesizes current evidence on the mechanisms such as regulating the intestinal barrier, immunomodulation, mediating anti-inflammatory metabolites and regulating microbiota and therapeutic potential of A. muciniphila in inflammation-related diseases. Integrating these with experimental/clinical data across inflammation-related disorders establishes a coherent framework. Beyond live bacteria, advances in pasteurized formulations and bioactive derivatives highlight complementary advantages.
No takes yet. Share an insight, caveat, or question.
Xie et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: